RITUXAN (Rituximab) Non-Hodgkin's Lymphoma

ReimbursementReimbursement

 

At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe medicines should be effective, safe and accessible to the patients who need them.

RITUXAN Access Solutions provides coverage and reimbursement support, patient assistance and informational resources for both patients and their health care providers.

RITUXAN Access Solutions

At RITUXAN Access Solutions, we're here to help find a way for you to get the medicine your doctor has prescribed, even if you have no insurance or have a problem paying for a Genentech medicine.

When you or your doctor's office call RITUXAN Access Solutions, you will connect with one of our experts, whose sole job is to make sure that you get the coverage or reimbursement help you need.

At RITUXAN Access Solutions, we work hard to make information you need about coverage and reimbursement easily available 24 hours a day:

  • via phone at 1-888-249-4918 between the hours of 6 a.m. and 5 p.m. PST Monday through Friday or
  • 24/7 through our website at www.RituxanAccessSolutions.com

Genentech® Access to Care Foundation

The Genentech Access to Care Foundation was established to help qualified patients with unmet medical needs to receive proper medical treatment. The Genentech Access to Care Foundation may be available to help those who are not able to obtain RITUXAN for financial reasons.

  • If you have no insurance, or you are effectively uninsured because your health insurance plan denies you access to RITUXAN, you can apply to the Genentech Access to Care Foundation for help with your treatment.
  • We recognize the financial burdens that some patients and their families may experience in gaining access to our medicines. We are committed to assisting all eligible patients obtain access to our medicines, regardless of their ability to pay.
  • For eligible patients who are treated in the United States, the Genentech Access to Care Foundation will provide medicine to those who cannot afford to pay for it because it is the right thing to do.

 

Links

INDICATIONS

RITUXAN® (rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

IMPORTANT SAFETY INFORMATION

RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.

Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.

Please read the Medication Guide in HTML or PDF versions for more information.